RPSM
ZBIO

Royalty Pharma Sub-Manager’s Zenas BioPharma ZBIO Stock Holding History

Royalty Pharma Sub-Manager’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.6M Hold
2,388,150
– – 25.05% 2
2026
Q1 		$46.7M Buy
2,388,150
+1,125,000
+89% +$25.3M 27.02% 2
2025
Q4 		$45.9M Buy
+1,263,150
New +$41.5M 26.77% 2

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royalty Pharma Sub-Manager's ZBIO Position: Q2 2026 in Review

Royalty Pharma Sub-Manager held its Zenas BioPharma (ZBIO) position steady in Q2 2026 at 2,388,150 shares worth $60.6M. The position accounts for 25.05% of the portfolio, ranked #2.

Royalty Pharma Sub-Manager first reported a position in ZBIO in Q4 2025 and has held it in 3 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Royalty Pharma Sub-Manager held 2,388,150 shares of Zenas BioPharma worth $60.6M as of Q2 2026.
  • Royalty Pharma Sub-Manager left its Zenas BioPharma share count unchanged in Q2 2026.
  • Zenas BioPharma made up 25.05% of Royalty Pharma Sub-Manager's portfolio in Q2 2026, its #2 holding.
  • Royalty Pharma Sub-Manager first reported a position in Zenas BioPharma in Q4 2025 and has held it in 3 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Royalty Pharma Sub-Manager's 13F filing for Q2 2026, filed 14 Aug 2026.